HOME > BUSINESS > Article

Text Size

small

medium

large


Sumitomo Dainippon Pharma to Invest 3 B. Dollars in European Startup

Sumitomo Dainippon Pharma to Invest 3 B. Dollars in European Startup

   Tokyo, Sept. 6 (Jiji Press)--Sumitomo Dainippon Pharma Co. <4506> said Friday it has struck a 3-billion-dollar investment deal with Roivant Sciences Ltd., a European drug startup.
   The basic agreement, aimed at capitalizing on Roivant's drug development capabilities and acquiring promising candidate drugs, has swept away concerns over a decline in Sumitomo Dainippon's earnings after its patent for the Latuda antipsychotic, whose sales account for 40 pct of its total, expires in the United States in February 2023, Hiroshi Nomura, president of the Osaka-based firm, said at a press conference at the firm's Tokyo head office.

To read a full story, please click here to find out how to subscribe.

BUSINESS

Aomori Tourism Information

HEADLINES

POLITICS
Japan Foreign Min. Motegi to Meet US State Sec. Pompeo in New York Next Week
ECONOMY
Japan Ready to Release Oil Reserves as Needed: Industry Minister Sugawara
SPORTS
Women's Volleyball: Japan Loses to S. Korea at World Cup, after Loss to Russia
OTHER
Japanese Princess Kako Meets with Austrian Pres. Van der Bellen in Vienna

Aomori Tourism Information

GOSHOGAWARA
Introduction of Tachineputa, Town of Kanagi and West Tsugaru Peninsula
・ GOSHOGAWARA 1
・ GOSHOGAWARA 2
・ GOSHOGAWARA 3
JOMON
An early culture with pottery
・ JOMON 1
・ JOMON 2
・ JOMON 3
・ JOMON 4

AFP-JIJI PRESS NEWS JOURNAL


Photos